Strides Pharma Science Ltd announced the outcome of their earnings call for the quarter and nine months ended December 31, 2024, highlighting a gross margin of 58% and a focus on reducing net debt to achieve a target of being debt-free within 2-3 years, indicating plans for annual capital expenditures of INR 150-200 crores.